David Shaw’s Definium Therapeutics DFTX Stock Holding History

David Shaw’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.8M	Buy	315,410 +43,693	+16%	+$1.08M	0.01%	1516
2026 Q1	$5.14M	Sell	271,717 -22,005	-7%	-$373K	﹤0.01%	2147
2025 Q4	$3.93M	Buy	293,722 +77,388	+36%	+$958K	﹤0.01%	2507
2025 Q3	$2.55M	Buy	216,334 +157,570	+268%	+$1.47M	﹤0.01%	2795
2025 Q2	$381K	Sell	58,764 -4,485	-7%	-$29.5K	﹤0.01%	3759
2025 Q1	$370K	Buy	+63,249	New	+$453K	﹤0.01%	3661
2024 Q2	–	Sell	-183,029	Closed	-$1.72M	–	4701
2024 Q1	$1.72M	Buy	+183,029	New	+$1.04M	﹤0.01%	2740
2022 Q1	–	Sell	-11,147	Closed	-$231K	–	5796
2021 Q4	$231K	Sell	11,147 -221	-2%	-$7.05K	﹤0.01%	4810
2021 Q3	$397K	Buy	11,368 +2,514	+28%	+$109K	﹤0.01%	4215
2021 Q2	$458K	Buy	+8,854	New	+$465K	﹤0.01%	4078

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

David Shaw's DFTX Position: Q2 2026 in Review

David Shaw increased its Definium Therapeutics (DFTX) stake by 16% in Q2 2026, buying an estimated $1.08M and bringing the position to 315,410 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1516.

David Shaw first reported a position in DFTX in Q2 2021 and has held it in 10 quarters since. 360 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

David Shaw held 315,410 shares of Definium Therapeutics worth $14.8M as of Q2 2026.
David Shaw bought 43,693 Definium Therapeutics shares in Q2 2026, an estimated $1.08M.
Definium Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1516 holding.
David Shaw first reported a position in Definium Therapeutics in Q2 2021 and has held it in 10 quarters since.
360 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.